Ipratropium bromide/salbutamol
| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| Clinical data | |
| Pregnancy category |
|
| Legal status | |
| Routes of administration | Inhalation |
| Identifiers | |
| ATC code | R03AK04 |
| (verify) | |
The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide (an anticholinergic) and salbutamol sulfate (albuterol sulfate, a β2-adrenergic receptor agonist) used in the management of chronic obstructive pulmonary disease (COPD) and asthma (not an FDA approved usage).[2] It is marketed by Boehringer Ingelheim as a metered dose inhaler (MDI) and nebuliser under the trade name Combivent. It is also marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva. The chemical is sold in India by Cipla as duolin. [3]
Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.
External links
References
- ↑ http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Combivent+IA/combivent.pdf
- ↑ "Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma.". ): National Institutes of Health. National Heart, Lung, and Blood Institute. 2007.
- ↑ http://www.cipladoc.com/therapeutic/admin.php?mode=prod&action=disp&id=240
- National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||